This research aims to evaluate two new pharmaceuticals on the market. Rimegepant and Lasmiditan target the trigeminovascular system and respectively, are characterized in the gepant and ditan classes of pharmaceuticals. Based on a review of studies, Rimegepant was determined to be the advantageous acute treatment. This is not conclusive due to inequivalent comparison in sample size and amount of research completed. It is encouraged for additional research to be imposed before a conclusive determination of the advantageous acute treatment can be distinguished.
Bachelor of Science (B.S.)
College of Medicine
Johnson, Tiffany A., "Determining the Advantageous Acute Migraine Treatment: Rimegepant and Lasmiditan Review of Literature" (2020). Honors Undergraduate Theses. 860.